Oregonians have paid 10 times more for top-selling prescription drugs due to deals between drug manufacturers to delay generics.
The 20 top prescription drugs that paid off their rivals to keep generics off the market resulted in average delays of five years that left patients paying up to 33 times as much for brand names, according to a report released Thursday from the Oregon State Public Interest Group and Community Catalyst. The drugs listed include some common prescriptions: Lipitor, Tamoxifen and Cipro.
The report comes in the midst of heightened efforts nationwide to rein in health care costs, including from prescription drugs. The Supreme Court ruled last month that the Federal Trade Commission can sue companies for paying rivals to keep generic drugs off the shelves.
Read more at OregonLive.com.